PRIME MEDICINE INC. - COMMON STOCK

3,1500

24-января-25 16:45:00

15 мин. задержка

Акции

-0,1100

-3,37%

Сегодняшний диапазон

3,1300 - 3,3400

ISIN

N/A

Источник

NASDAQ

Prime Medicine to Present at 43rd Annual J.P. Morgan Healthcare Conference

07 янв 2025 08:00:01 Источник Nasdaq GlobeNewswire
Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates

12 ноя 2024 16:00:00 Источник Nasdaq GlobeNewswire
Prime Medicine to Participate in Upcoming Investor Conferences

06 ноя 2024 16:00:00 Источник Nasdaq GlobeNewswire
Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson’s Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress

24 окт 2024 08:00:00 Источник Nasdaq GlobeNewswire
Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific Meetings

15 окт 2024 08:00:00 Источник Nasdaq GlobeNewswire
Prime Medicine Unveils Strategically Focused Pipeline

30 сен 2024 07:01:00 Источник Nasdaq GlobeNewswire
Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies

30 сен 2024 07:00:00 Источник Nasdaq GlobeNewswire
Prime Medicine to Participate in Upcoming Investor Conferences

28 авг 2024 08:00:00 Источник Nasdaq GlobeNewswire
Prime Medicine Reports Second Quarter 2024 Financial Results and Provides Business Updates

08 авг 2024 08:00:00 Источник Nasdaq GlobeNewswire
Prime Medicine to Present at Upcoming Investor Conferences

30 май 2024 08:00:00 Источник Nasdaq GlobeNewswire
Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

13 май 2024 08:00:00 Источник Nasdaq GlobeNewswire
Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates

10 май 2024 08:00:00 Источник Nasdaq GlobeNewswire
Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)

08 май 2024 08:00:00 Источник Nasdaq GlobeNewswire
Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference

01 май 2024 08:00:00 Источник Nasdaq GlobeNewswire
Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

29 апр 2024 07:00:00 Источник Nasdaq GlobeNewswire
Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings

23 апр 2024 08:00:00 Источник Nasdaq GlobeNewswire
Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates

01 мар 2024 08:00:00 Источник Nasdaq GlobeNewswire
Prime Medicine to Participate in Upcoming Investor Conferences

28 фев 2024 08:00:00 Источник Nasdaq GlobeNewswire
Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

20 фев 2024 16:01:00 Источник Nasdaq GlobeNewswire
Prime Medicine Announces Pricing of Upsized Public Offering

14 фев 2024 23:50:13 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.